Why I’d ditch buy-to-let property and buy these 2 FTSE 100 growth shares today

I think that these two FTSE 100 (INDEXFTSE:UKX) shares could offer long-term growth potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With house prices being close to record levels when compared to average incomes, the capital growth potential of buy-to-let investments may be somewhat limited.

By contrast, the FTSE 100 appears to offer significant long-term growth prospects. A number of its members trade on fair valuations, and are expected to post improving financial performances as they deliver on their strategies.

Here are two prime examples of such companies. Buying them now could be a worthwhile move, since they may outperform buy-to-let investments in the coming years.

AstraZeneca

The recent third-quarter update from AstraZeneca (LSE: AZN) highlighted the rapid pace of growth that the FTSE 100 pharmaceutical company is experiencing. Its core earnings increased by 36% in the quarter compared to the same period of the prior year. This highlights the success of its strategy, with the company’s pipeline suggesting that a rapid rate of growth may be maintained over the long run.

As a result of its improving financial performance, the stock now trades on a price-to-earnings (P/E) ratio of around 27. While this may seem to be high, the stock is forecast to post a rise in its bottom line of 20% next year. This could justify its current valuation – especially since its balance sheet and cash flow provide the financial firepower it needs to maintain a high level of investment in its pipeline.

AstraZeneca’s defensive characteristics may appeal to investors in 2020. The company’s financial performance is less dependent on the wider economy than is the case for many of its FTSE 100 peers. As such, now could be the right time to buy a slice of it, with its current growth strategy set to lead to an improving share price performance.

Burberry

Another FTSE 100 share that has a solid growth strategy is Burberry (LSE: BRBY). The premium fashion business has changed its senior management team in the last few years, and is embarking on major strategy shifts that seem to be working well.

For example, it is working to move even more upmarket, is cutting costs, has launched a wide range of new products under its new creative head that are proving popular with consumers, and is seeking to boost its sales through the use of social media and influencers. Its focus on its highest-end  luxury products also involves store closures and store upgrades, all of it potentially leading to improving financial performance.

Although Burberry’s share price now trades on a P/E ratio of 24, it is forecast to produce a 10% rise in net profit next year. Beyond this, its exposure to fast-growing consumer markets across Asia could strengthen its investment appeal. Therefore, while there may be cheaper stocks available in the FTSE 100, the company’s financial prospects and its economic moat that is derived from a high degree of brand loyalty could lead to significant capital growth in the coming years.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca and Burberry. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is AMC stock on the move again?

Investors who remember the meme stock frenzy of 2021 will wonder if the same can ever happen again. With AMC…

Read more »

Investing Articles

‘Britain’s Warren Buffett’ just bought 262,959 shares of this magnificent stock

In the first quarter of 2024, Fundsmith portfolio manager Terry Smith (aka the UK's 'Warren Buffett’) was buying this blue-chip…

Read more »

Close-up of British bank notes
Dividend Shares

If I was starting a high-yield dividend stock portfolio today, here are 3 shares I’d buy

High-yield dividend stocks can be a great way to generate income. But it can pay to be selective when building…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Growth Shares

This AIM stock could rise 51%, according to a City broker

This AIM stock has been moving higher recently. However, analysts at Deutsche Bank believe its share price has a lot…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

1 top FTSE 100 growth stock to consider buying before the end of May

Consistent growth from this FTSE 100 performer looks set to continue, so I’d consider the shares now for a diversified…

Read more »

Investing Articles

Here’s where I see the Legal & General share price ending 2024

After a choppy start to the year, Charlie Carman explores where the Legal & General share price could go over…

Read more »

Investing Articles

3 steps to earning £100 a month in passive income

Earning passive income from stocks is simple but not easy. Stephen Wright outlines the way to aim for £100 per…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

Where will the Rolls-Royce share price end 2024, above 500p or below 400p?

Will the Rolls-Royce share price ride higher in 2024, or will we see a fall back to lower valuations? Either…

Read more »